Rein Therapeutics, Inc.
Rein Therapeutics, Inc. (Nasdaq Capital Market: ticker symbol not specified in document) operates as a clinical-stage biopharmaceutical company focused on developing novel therapies for orphan pulmonary and fibrosis indications with limited or no approved treatments. The company changed its name from Aileron… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rein Therapeutics, Inc. does
In the company’s own words
Rein Therapeutics, Inc. (Nasdaq Capital Market: ticker symbol not specified in document) operates as a clinical-stage biopharmaceutical company focused on developing novel therapies for orphan pulmonary and fibrosis indications with limited or no approved treatments. The company changed its name from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc. effective January 10, 2025.
The company's pipeline centers on LTI-03, a peptide derived from the endogenous protein Caveolin-1 (Cav1) designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis (IPF) patients. LTI-03 has received Orphan Drug Designation in the United States and European Union. The company initiated its Phase 2 RENEW clinical trial in May 2025, enrolling approximately 120 IPF patients across up to 50 sites globally, including locations in the United States, United Kingdom, Germany, Australia, and Poland. The trial evaluates safety, tolerability, and efficacy while assessing biomarkers and lung function measurements. The company dosed its first patient in the RENEW trial in March 2026 and expects to report initial interim topline data in the fourth quarter of 2026.
The company's secondary product candidate, LTI-01, is a single-chain urokinase plasminogen activator for treating loculated pleural effusion, an orphan disorder with no approved therapeutics. LTI-01 completed Phase 2a and Phase 1b clinical trials but development has been paused indefinitely due to capital constraints, with resources prioritized toward LTI-03. The company also maintains preclinical programs targeting cystic fibrosis and systemic fibrosis indications, though these programs are similarly suspended pending additional financing.
Rein does not operate manufacturing facilities and relies entirely on third-party contract manufacturers for producing all product candidates. The company has no current marketing, sales, or distribution capabilities and anticipates establishing these functions or partnering with established pharmaceutical companies for any approved products. As of March 24, 2026, the company owns or has licensed fifty-eight issued patents and fifty-two pending patent applications worldwide related to its lung business programs.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1420565
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rein Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rein Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rein Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rein Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rein Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”